## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
Name and Address of Reporting Person*  Davar Nipun				2. Issuer Name <b>and</b> Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below) Other (specify below)  Vice President				
(Last) (First) (Middle) C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 10/13/2014										vice Freside	nt .	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							equir	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Year	(Instr. 8)		4. Securities Acc (A) or Disposed (Instr. 3, 4 and 5		d of (I	of (D) Benefici		unt of Securities ially Owned Following d Transaction(s) and 4)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
				Co	ode	V	Amoun	(A) or (D)	Pric	ice				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock		10/13/2014		]	P		3,000	A	\$ 2.98	85	3,000			D		
Reminder:	Report on a s	eparate line fo		Derivative Securi	ties Ac	equir	Pers cont the f	sons whatained if form dis	no resp n this f splays of, or B	orm a a cur	are irrent	not requ tly valid		ormation spond unle rol numbe	ss	1474 (9-02)
	I_			(e.g., puts, calls, w		ts, op								0.37	2 4 2	14. 37.
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) any (Month/Day/Year) Code (Instr. 8) of Derivative Securities (Month/Day/Year)		A U S (I	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	Ownershi (Instr. 4) D) ect						
				Code V	(A)	(D)	Date Exer	e rcisable	Expirat Date	ion T	Γitle	Amount or Number of Shares				

### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Davar Nipun C/O THRESHOLD PHARMACEUTICALS, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO, CA 94080			Vice President				

### **Signatures**

/s/ Nipun Davar	10/13/2014				
**Signature of Reporting Person	Date				

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.